Six Shots a Year Can Prevent HIV

spot_img

A new study shows that six shots a year of an antiretroviral (ARV) Drug can prevent HIV in women. This new injection is said to be more effective than daily HIV pills, at preventing HIV in women. Even though it won’t be available immediately, countries should start planning to introduce these bimonthly injections.

This study is a game-changer, especially for women in Sub-Saharan Africa. According to UN 2019 AIDS data, they make up 60% of all new HIV infections in the continent.

Prevent HIV
Civil rights activists march in Durban, South Africa, Monday, July 18, 2016, at the start of the 21st World Aids Conference. U.N. Secretary-General Ban Ki-moon told reporters Monday that the gains the world has made against AIDS are “inadequate and fragile.” He said more than half the people around the world infected with HIV, or 20 million people, still don’t have access to treatment. (AP Photo)

Zambian activist, Chilufya Kasanda Hampongo, said, “A new HIV-prevention option for women is cause for celebration. We know that [ensuring people have a] real choice in HIV prevention depends on giving women — and all people — full information about risks and benefits … and making sure that those methods are available.”

How the bimonthly injections prevent HIV

The study was conducted among 2,300 women. It found that bimonthly injections of cabotegravir (long-lasting ARV) were 89% more effective than daily HIV pill, Truvada, in preventing HIV. The research was conducted in seven African countries.

Truvada combines ARVs emtricitabine and tenofovir. The United States Centers for Disease Control and Prevention says that when taken correctly, it can reduce the risk of contracting HIV down to 1%. However, since women have to take this pill daily, it can get hard to adhere to the medication for some.

Sinead Delany-Moretlwe, the study’s lead researcher, who is also the director of research at the Wits Reproductive Health and HIV Institute in Johannesburg says that the injection turned out to be better than Truvada since it was easier for women to take, than daily pills.

Truvada to prevent HIV

“The challenge with Truvada is that it relies on consistent daily pill-taking,” she says. “[We found that] cabotegravir is far superior to Truvada in preventing infection and we think that’s because of adherence.”

Yvette Raphael, executive director of the South African organisation Advocacy for Prevention of HIV and AIDS says that the injection will never replace the HIV prevention pill for everyone. Instead, it will be offered alongside Truvada to ensure that people have the choice to choose what works for them.

Out of all the women who participated in the study, 38 got infected with HIV while taking part in the research. 4 of these women were on the bimonthly injection. Scientists are still trying to study these infections further and understand why they happened. In spite of this, AVAC, a US-based HIV prevention organisation notes that this is the lowest rate of new infections in any similar study of Truvada in women.

The results of this study were expected to come after 2022, but an independent monitoring board came to the conclusion that the results were strong enough, both in terms of safety and effectiveness, to release early findings. All the women involved in the study will have the opportunity to take the injection until the end of the study, which may last another two years, Delany-Moretlwe says.

Looking Ahead

Delany-Moretlwe says that this bi-monthly injection won’t be available for the public for a few more years. Scientists have to conduct further research, and pharmaceutical manufacturer Viiv Healthcare will have to get approval from international and national regulatory bodies to market the injection.

In the meantime, many activists are encouraging countries to plan how they might use and pay for this injection. They also warned that countries will have to expand access to Truvada to prevent HIV. Nevertheless, the findings of the study are an excellent tool in the journey towards preventing HIV.

Further Reading:

Jhanvi Kotak
Jhanvi is an introvert nerd. who sometimes claims she can be extrovert too. An economics student, book reader and foody sums her up pretty well.

Leave a Reply

Latest posts

PUBG Might Be Going Free to Play on PC

A trusted source has leaked a new game plan by PUBG Corporation to increase the lifespan of the 4-Year-Old game. Fortnite, Apex Legends, CSGO,...

The NetherRealm Marvel Game Roster Might Have Already Been Leaked

The NetherRealm Marvel game hasn’t even properly been announced yet, and there are already some leaks about the roster and gameplay that it is...

Redmi Note 10T 5G Review – 5G Normalized

It’s a new day, and there’s a new Xiaomi phone to play with. Xiaomi’s crack at the budget 5G market comes as an anticipated...
Advertisment

Loading Next Article